Active Biotech

Active Biotech is a Swedish biopharmaceutical company focused on modulating the immune system to treat cancer and inflammatory eye diseases. Its strategy centers on repurposing and advancing a portfolio of assets with extensive prior clinical data, including tasquinimod for hematological cancers and laquinimod for uveitis, to achieve efficient development in high-value niches. The company maintains a lean operational model, with key programs either fully owned or strategically partnered, such as naptumomab with NeoTX for solid tumors.

Deep expertise in immunomodulation applied to two modalities: small molecule quinoline-3-carboxamides (e.g., tasquinimod, laquinimod) for oral and topical use, and antibody-based tumor-targeted superantigen (TTS) immunotherapy.

In myelofibrosis, tasquinimod competes with JAK inhibitors and novel agents, differentiating via microenvironment modulation. In uveitis, laquinimod eye drops face competition from steroids and biologics but offer a unique topical mechanism. Naptumomab enters a crowded solid tumor immunotherapy field.